RGEN
REPLIGEN CORPCompany Information
- Company Name
- REPLIGEN CORP
- CIK
- CIK0000730272
- Category
- Large accelerated filer
- Ticker: Exchange
- RGEN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- RGEN
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-08
- Last sale
- 2026-09-24
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 86,435
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 62,207,636
- Shares outstanding
- 56,418,000
- Ownership
- 110.26%
Earnings Market Reaction
- Filing date
- 2026-07-29
- Price on filing date
- —
- 1-month reaction
- 28.25%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 607 | 583 | 566 | 749 | 709 | 697 | 757 | 784 | 809 | 781 | 751 | 631 | ||||||
| Held To Maturity Securities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Marketable Securities Current | 204 | 202 | 202 | - | - | - | 0 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 158 | 152 | 159 | 149 | 157 | 147 | 134 | 129 | 123 | 116 | 124 | 106 | ||||||
| Inventory Net | 187 | 179 | 170 | 160 | 156 | 153 | 143 | 182 | 191 | 198 | 202 | 211 | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | - | - | - | 1 | 1 | - | - | ||||||
| Prepaid Expense And Other Assets Current | 46 | 46 | 41 | 38 | 35 | 35 | 32 | 36 | 33 | 36 | 34 | 32 | ||||||
| Assets Current | 1,201 | 1,161 | 1,137 | 1,096 | 1,057 | 1,032 | 1,066 | 1,132 | 1,157 | 1,131 | 1,111 | 980 | ||||||
| Property Plant And Equipment Net | 168 | 173 | 187 | 189 | 193 | 196 | 198 | 203 | 205 | 206 | 207 | 202 | ||||||
| Intangible Assets Net Excluding Goodwill | 358 | 368 | 386 | 395 | 406 | 409 | 398 | 381 | 386 | 394 | 407 | 350 | ||||||
| Goodwill | 1,104 | 1,107 | 1,114 | 1,113 | 1,114 | 1,082 | 1,031 | 988 | 986 | 986 | 987 | 869 | ||||||
| Deferred Income Tax Assets Net | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 2 | 2 | ||||||
| Operating Lease Right Of Use Asset | 116 | 114 | 120 | 124 | 128 | 130 | 135 | 127 | 131 | 135 | 116 | 118 | ||||||
| Other Assets Noncurrent | 4 | 6 | 5 | 5 | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Assets Noncurrent | - | - | 1,812 | 1,827 | 1,845 | 1,820 | 1,764 | 1,699 | 1,709 | 1,723 | 1,720 | 1,542 | ||||||
| Assets | 2,950 | 2,931 | 2,950 | 2,924 | 2,902 | 2,852 | 2,830 | 2,831 | 2,866 | 2,854 | 2,831 | 2,523 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 33 | 35 | 30 | 29 | 26 | 27 | 32 | 21 | 21 | 19 | 20 | 19 | ||||||
| Operating Lease Liability Current | 19 | 21 | 22 | 19 | 16 | 15 | 15 | 12 | 12 | 10 | 6 | 3 | ||||||
| Business Combination Contingent Consideration Liability Current | 3 | 5 | 5 | 5 | 5 | 34 | 17 | 14 | 14 | 24 | 13 | 13 | ||||||
| Convertible Notes Payable Current | - | - | - | - | - | - | 0 | 0 | 69 | 69 | 69 | 286 | ||||||
| Accrued Liabilities Current | 77 | 65 | 79 | 77 | 76 | 76 | 62 | 61 | 58 | 59 | 57 | 58 | ||||||
| Liabilities Current | 133 | 126 | 136 | 131 | 123 | 152 | 127 | 108 | 175 | 182 | 165 | 379 | ||||||
| Convertible Debt Noncurrent | - | - | - | - | 534 | 530 | 526 | 522 | 518 | 514 | 510 | - | ||||||
| Long Term Debt | 551 | 547 | 542 | 538 | - | - | 526 | - | - | - | - | - | ||||||
| Deferred Tax And Other Liabilities Noncurrent | 17 | 15 | 22 | 20 | 23 | 24 | 23 | 34 | 34 | 37 | 39 | 15 | ||||||
| Operating Lease Liability Noncurrent | 121 | 120 | 126 | 132 | 136 | 139 | 146 | 139 | 144 | 145 | 127 | 131 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | 0 | 1 | 1 | 2 | 7 | 5 | 20 | 0 | 0 | 0 | 14 | 14 | ||||||
| Other Liabilities Noncurrent | 17 | 17 | 16 | 17 | 17 | 17 | 17 | 12 | 11 | 11 | 11 | 11 | ||||||
| Liabilities Noncurrent | - | - | 708 | 709 | 717 | 715 | 730 | 706 | 707 | 707 | 701 | 170 | ||||||
| Liabilities | 838 | 825 | 844 | 841 | 840 | 867 | 857 | 814 | 882 | 888 | 866 | 549 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Additional Paid In Capital Common Stock | 1,662 | 1,655 | 1,652 | 1,644 | 1,635 | 1,620 | 1,617 | 1,610 | 1,586 | 1,572 | 1,569 | 1,567 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -20 | -14 | -3 | -4 | -2 | -48 | -53 | -35 | -44 | -43 | -38 | -43 | ||||||
| Retained Earnings Accumulated Deficit | 470 | 465 | 456 | 443 | 428 | 413 | 407 | 441 | 442 | 436 | 433 | 449 | ||||||
| Stockholders Equity | 2,112 | 2,105 | 2,106 | 2,083 | 2,062 | 1,985 | 1,973 | 2,017 | 1,984 | 1,966 | 1,965 | 1,974 | ||||||
| Liabilities And Stockholders Equity | 2,950 | 2,931 | 2,950 | 2,924 | 2,902 | 2,852 | 2,830 | 2,831 | 2,866 | 2,854 | 2,831 | 2,523 | ||||||
| Allowance For Doubtful Accounts Receivable Current | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | 80 | ||||||
| Common Stock Shares Issued | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | ||||||
| Shares Outstanding | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | 56 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialREPLIGEN CORP (RGEN) — SEC Financial Statements & Analysis
REPLIGEN CORP (RGEN) is a biological products, (no diagnostic substances) company, incorporated in DE. REPLIGEN CORP trades on Nasdaq as: RGEN. REPLIGEN CORP (RGEN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29. Based on that filing, REPLIGEN CORP carries a market cap of $7.70B, a P/E ratio of 185.31x, a P/B ratio of 3.64x, a P/S ratio of 9.80x, an enterprise value of $7.64B, and an EV/EBITDA multiple of 53.28x. On profitability, it posts a gross margin of 53.52%, an operating margin of 8.23%, a net margin of 5.29%, a Return on Equity (ROE) of 1.99%, a Return on Assets (ROA) of 1.42%, and a Return on Invested Capital (ROIC) of 2.59%. Per share, it reports EPS of $0.74, diluted EPS of $0.73, free cash flow per share of $1.98, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 16.49% year-over-year, net income growth of -400.42% year-over-year, and EPS growth of -399.44% year-over-year. On the balance sheet, it maintains a current ratio of 9.05x, a quick ratio of 7.30x, working capital of $1.07B, a debt-to-equity ratio of 0.40x, a debt ratio of 0.28, an interest coverage ratio of 2.92x, free cash flow of $111.97M (TTM), and net debt of $-57.76M. Figures sourced from SEC EDGAR.
- Market Cap
- $7.70B
- P/E TTM
- 185.31x
- EPS TTM
- $0.74
- P/B TTM
- 3.64x
- ROE TTM
- 1.99%
- ROA TTM
- 1.42%
- Debt To Equity
- 0.40x
- Free Cash Flow TTM
- $111.97M
- Net Revenue TTM Growth 1Y
- 16.49%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is REPLIGEN CORP in?
REPLIGEN CORP (RGEN) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does RGEN trade on?
REPLIGEN CORP (RGEN) trades on the Nasdaq.
Where is REPLIGEN CORP incorporated?
REPLIGEN CORP is incorporated in DE.
When was REPLIGEN CORP (RGEN)'s most recent SEC filing?
REPLIGEN CORP (RGEN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29.
What is RGEN's market cap?
REPLIGEN CORP (RGEN) has a market capitalization of $7.70B as of 2026-06-30.
What is RGEN's P/E ratio?
REPLIGEN CORP (RGEN)'s trailing twelve month P/E ratio is 185.31x as of 2026-06-30.
What is RGEN's EPS (earnings per share)?
REPLIGEN CORP (RGEN)'s trailing twelve month EPS is $0.74 as of 2026-06-30.
What is RGEN's ROE (return on equity)?
REPLIGEN CORP (RGEN)'s trailing twelve month Return on Equity (ROE) is 1.99% as of 2026-06-30.
What is RGEN's ROA (return on assets)?
REPLIGEN CORP (RGEN)'s trailing twelve month Return on Assets (ROA) is 1.42% as of 2026-06-30.
What is RGEN's ROIC (return on invested capital)?
REPLIGEN CORP (RGEN)'s trailing twelve month Return on Invested Capital (ROIC) is 2.59% as of 2026-06-30.
What is RGEN's EV/EBITDA?
REPLIGEN CORP (RGEN)'s trailing twelve month EV/EBITDA is 53.28x as of 2026-06-30.